SecBot SecBot

TRAX

First Tracks Biotherapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002091349 Biotech & Drug Discovery
$44.05 +0.91 (+2.11%)
Oct 23 4:00 PM ET · prev $43.14
Market cap
$1.8B
Small cap
Consensus
Buy
94% Buy or better · 18 analysts
Median target
🔒 Subscribers only
Since first trade
+131.8%
from $19.00 · Apr 6
30 days
+22.9%
from $35.83
Range since listing
$15.32–47.92
−8% from high · low Jun 3
Avg volume 20D
1.23M
Oct 12 spike 7.31M
Short interest
5.19M
≈14.5% of shares · +15.3%
Days to cover
6.2
at average volume
Insider net
-$1.8M
0 buyers · 1 seller · since Apr 21
New fund stakes
11
Q2 2026 13F · 0 exits
Filing reports
19
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 2 bearish · 3 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 7/8
Strongest BULLISH First Tracks Biotherapeutics announced positive top-line results from Cohort 1 of ANB033's Phase 1b…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $1.8M.

  • InstitutionsBULLISH

    Q2 2026: 11 added (11 new), 0 trimmed or exited. Largest new: Fmr $41.3M, Blackrock, $39.5M.

  • AnalystsBULLISH

    17 of 18 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +15.3% to 5.19M shares. 6.2 days to cover, ≈14.5% of shares.

  • TrendRANGE

    14% above its 50-day average.

Who's buying

13F· Q2 2026
11
new positions
0
exits
$241.9M
in new stakes
FundMoveSharesValue
FMR LLCNEW2,054,127$41.3M
BlackRock, Inc.NEW1,963,541$39.5M
STATE STREET CORPNEW1,512,896$30.4M
VANGUARD CAPITAL MANAGEMENT LLCNEW1,451,909$29.2M
Woodline Partners LPNEW917,176$18.5M
MORGAN STANLEYNEW781,534$15.7M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW729,000$14.7M
BALYASNY ASSET MANAGEMENT L.P.NEW714,948$14.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy11Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 16, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Oct 13, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 13, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Oct 13, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Sep 30, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Sep 18, 2026Evercore ISI Group
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$1.8M
sold · 1 insider
DateInsiderTypeValue
Sep 15, 2026
Orwin John A
Director
EXERCISE1,300 sh
Sep 2, 2026
Ware J. Anthony
Director
EXERCISE10,694 sh
Sep 2, 2026
Ware J. Anthony
Director
EXERCISE28,571 sh
Sep 2, 2026
Ware J. Anthony
Director
SELL$1.8M
Sep 2, 2026
Ware J. Anthony
Director
EXERCISE$225.4K
Aug 15, 2026
Lizzul Paul F.
Chief Medical Officer
AWARD60,492 sh
Aug 15, 2026
STONE BENJAMIN
Chief Business Officer
AWARD60,492 sh
Aug 15, 2026
Faga Daniel
President, CEO
AWARD193,575 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
5,190,809
shares short
+15.3%
vs prior settlement
6.2
days to cover
≈14.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h) — subscribers only
Oct 20, 2026 SEC
First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of common stock on October 19, 2026, and…
8-K — Impact 2/10
Oct 15, 2026 SEC
First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 shares of common stock at…
8-K — Impact 6/10
Oct 15, 2026 Press
First Tracks Biotherapeutics announced a $200M private placement of 6.1M shares at $32.75/share, with proceeds for…
Impact 6/10
Oct 15, 2026 Offering
First Tracks Biotherapeutics Announces $200 Million Private Placement
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a cl
Sep 15, 2026 Insider
Orwin John A acquired via exercise 1,300 shares
Director
Sep 2, 2026 Insider
Ware J. Anthony acquired via exercise 10,694 shares
Director
Sep 2, 2026 Insider
Ware J. Anthony acquired via exercise 28,571 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Offering
First Tracks Biotherapeutics Announces $200 Million Private Placement
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing…
Aug 26, 2026
Press release
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing…
Aug 12, 2026
Earnings
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing…
Jul 15, 2026
Short interest
Short Interest: TRAX up 22% to 4.8M shares
Settlement 2026-07-15 | Days to cover: 4.19 | ≈13.68% of shares outstanding (est.)
Jun 30, 2026
Short interest
Short Interest: TRAX up 33% to 3.9M shares
Settlement 2026-06-30 | Days to cover: 4.78 | ≈11.21% of shares outstanding (est.)

SecBot reports

19 filings · 1 press releases · 3 bullish · 1 bearish · 15 neutral
All TRAX filing & press-release reports (20)